AbbVie Cerevel acquisition closes in $8.7B neuroscience deal

Key Takeaways

• AbbVie completed the Cerevel buyout on August 1, 2024 for $45.00 per share (~$8.7 billion equity value), per PR Newswire and SEC disclosures.
• At announcement (December 6, 2023), AbbVie framed the pipeline around schizophrenia, Parkinson’s disease, and mood disorders, including emraclidine and tavapadon.
• EMPOWER-1 (NCT05227690) and EMPOWER-2 (NCT05227703) missed their week-6 PANSS primary endpoint (November 11, 2024).
• AbbVie recorded a $3.5 billion after-tax emraclidine intangible impairment in 2024 results; remaining Cerevel intangibles were cited at about $3.6 billion.

When did the AbbVie Cerevel acquisition close and on what terms?

AbbVie announced completion of the Cerevel Therapeutics acquisition on August 1, 2024. It acquired all outstanding Cerevel common stock for $45.00 per share in cash, with Cerevel shares expected to cease NASDAQ trading before market open that day, according to a PR Newswire release.

AbbVie’s SEC notes state the total fair value of consideration transferred was $8.7 billion ($8.3 billion net of cash acquired). Management said the deal was expected to be accretive to adjusted diluted EPS beginning in 2030 and reaffirmed 2024 adjusted diluted EPS guidance of $10.71–$10.91, including a $0.19 per share dilutive impact from Cerevel.

What did AbbVie say it was buying in December 2023?

The December 6, 2023 definitive agreement valued Cerevel at approximately $8.7 billion equity value at $45.00 per share. AbbVie positioned Cerevel’s clinical and preclinical neuroscience candidates as complementary to its psychiatry, migraine, and Parkinson’s portfolio.

Programs highlighted at announcement included emraclidine (schizophrenia), tavapadon (Parkinson’s), and other assets spanning mood disorders. Closing was expected mid-2024 subject to shareholder and regulatory approvals—conditions later met with the August 1, 2024 close (announcement PR).

How did emraclidine Phase 2 EMPOWER results change the thesis?

On November 11, 2024, AbbVie reported that EMPOWER-1 and EMPOWER-2 did not meet the primary endpoint of a statistically significant reduction in PANSS total score versus placebo at week 6 in adults with an acute schizophrenia exacerbation.

• EMPOWER-1: NCT05227690 (10 mg and 30 mg CVL-231/emraclidine)
• EMPOWER-2: NCT05227703 (15 mg and 30 mg)
• Company said emraclidine was well tolerated, with headache, dry mouth, and dyspepsia among common adverse events (PR Newswire update)

That readout is the load-bearing clinical update after the close. Framing emraclidine as an untested upside catalyst after November 2024 would contradict AbbVie’s own disclosure.

What accounting impact followed the EMPOWER misses?

In full-year and fourth-quarter 2024 results, AbbVie said the EMPOWER misses prompted an impairment evaluation that sharply cut estimated future cash flows for emraclidine. The company recorded a non-cash after-tax intangible asset impairment of $3.5 billion and said it would monitor remaining Cerevel-related intangibles of about $3.6 billion (FY2024 results PR).

SEC business-combination notes confirm the August 1, 2024 acquisition accounting and $8.7 billion consideration, with purchase-price allocation finalized in the three months ended March 31, 2025 (AbbVie SEC note).

What else remains in the Cerevel neuroscience package?

Beyond emraclidine, AbbVie’s third-quarter 2024 commentary still listed tavapadon (D1/D5 partial agonist for Parkinson’s) and CVL-354 (kappa opioid receptor antagonist for major depressive disorder) as Cerevel programs of interest. Those assets were not the subject of the November EMPOWER PANSS miss.

Investors should track each program’s own registrational path rather than treat the $8.7 billion sticker as proof that every Cerevel asset will reach approval.

What remains unproven after the deal close?

Public releases do not establish that tavapadon or CVL-354 will offset the emraclidine setback on a net-present-value basis. AbbVie has not published a revised probability-weighted revenue bridge for the full Cerevel stack post-impairment in the sources cited here.

Next catalysts are program-specific trial readouts and any further intangible reviews AbbVie discloses in periodic filings—not another “deal close” event.

Related NovaPharma coverage

• AbbVie company profile
• Neurocrine Biosciences pipeline update: catalyst watch
• Vabysmo EU approval for retinal vein occlusion

Frequently Asked Questions

Primary Sources

1. PR Newswire: AbbVie completes Cerevel acquisition (Aug 1, 2024)
2. PR Newswire: Emraclidine EMPOWER Phase 2 update (Nov 11, 2024)
3. PR Newswire: AbbVie FY2024 results ($3.5B impairment)
4. ClinicalTrials.gov: EMPOWER-1 NCT05227690
5. SEC: AbbVie Cerevel acquisition accounting note